Clinical trial · Observational
Role of Biomarkers in Muscle Pain and Joint Pain in Patients With Solid Tumors Receiving Paclitaxel
The Role of COX-2 Mediated Prostaglandin Production on Paclitaxel-Induced Myalgias and Arthralgias.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): slow accrual
Summary
Brief summary (as posted)
RATIONALE: Learning about pain in patients with cancer receiving paclitaxel may help plan treatment and may help patients live more comfortably. Studying samples of urine from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to muscle and joint pain. PURPOSE: This phase I trial is studying the role of biomarkers in muscle pain and joint pain in patients with solid tumors receiving paclitaxel.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Arthralgia | — | UNRESOLVED | — |
| Pain | — | UNRESOLVED | — |
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| assessment of therapy complications | Procedure | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| questionnaire administration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Paclitaxel-Induced Myalgias/Arthralgias
- interventionNames
- Other: laboratory biomarker analysis
- Other: questionnaire administration
- Procedure: assessment of therapy complications
Primary outcomes (1)
- measure
- Change in urinary PGE-M level after paclitaxel treatment
- timeFrame
- Day 1 before paclitaxel treatment and day 4, after treatment
- description
- Change in amount of PGE-M in the urine from before administration of paclitaxel to 4 days after treatment.
Secondary outcomes (3)
- measure
- Correlation of change in urinary PEG-M level and paclitaxel dose
- timeFrame
- Day 1 before paclitaxel treatment and day 4, after treatment
- description
- Inter-relationship between the dose of paclitaxel and the change in level of urinary PEG-M from before treatment compared to day 4 of paclitxel treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Solid malignancy of any type * Patients must be scheduled to receive their first dose of paclitaxel at Vanderbilt-Ingram Cancer Center * Any paclitaxel-containing regimen or dosing schedule is allowed PATIENT CHARACTERISTICS: * Not pregnant * Accessible for follow-up * Able to submit urine samples * Able to complete questionnaires PRIOR CONCURRENT THERAPY: * See Disease Characteristics
References
Publications (0)
Data not yet available